Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14343164 | 0.82 | CNR1 (0.33) | CNR1CNR2 | |
| SCHEMBL730353 | 0.76 | — | — | |
| SCHEMBL29696957 | 0.76 | GPR84 (0.32) | — | |
| SCHEMBL30829735 | 0.74 | PARP1 (0.36) | CNR1CNR2 | |
| SCHEMBL656754 | 0.74 | PARP1 (0.36) | CNR1CNR2 | |
| SCHEMBL14075006 | 0.74 | — | — | |
| SCHEMBL3259921 | 0.73 | — | — | |
| SCHEMBL3107123 | 0.73 | — | — | |
| SCHEMBL284553 | 0.73 | GABRA1 (0.39) | — | |
| SCHEMBL1426960 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | CNR1 2310/4885CNR2 2367/4885 |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | HDAC6, SI, HDAC3 | CNR1 1057/4885CNR2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.